An open-label study to determine the maximum tolerated dose of the multitargeted tyrosine kinase inhibitor CEP-11981 in patients with advanced cancer

por Pili, Roberto, Carducci, Michael, Brown, Peter, Hurwitz, Herbert
Publicado 2014

A Phase I, first-in-human, open label, dose escalation study of MGD007, a humanized gpA33 × CD3 dual-affinity re-targeting (DART(®)) protein in patients with relapsed/refractory me...

por Hurwitz, Herbert, Crocenzi, Todd, Lohr, Joanna, Bonvini, Ezio, Johnson, Syd, Moore, Paul, Wigginton, Jon
Publicado 2014

Effects of the combination of TRC105 and bevacizumab on endothelial cell biology

por Liu, Yingmiao, Tian, Hongyu, Blobe, Gerard C., Theuer, Charles P., Hurwitz, Herbert I., Nixon, Andrew B.
Publicado 2014

Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies

por Cassidy, James, Saltz, Leonard B., Giantonio, Bruce J., Kabbinavar, Fairooz F., Hurwitz, Herbert I., Rohr, Ulrich-Peter
Publicado 2009

A Phase Ib study of ruxolitinib + gemcitabine ± nab-paclitaxel in patients with advanced solid tumors

por Bauer, Todd M, Patel, Manish R, Forero-Torres, Andres, George, Thomas J, Assad, Albert, Du, Yining, Hurwitz, Herbert
Publicado 2018

Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab

por Liu, Yingmiao, Starr, Mark D, Bulusu, Anuradha, Pang, Herbert, Wong, Nan Soon, Honeycutt, Wanda, Amara, Anthony, Hurwitz, Herbert I, Nixon, Andrew B
Publicado 2013

Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer

por Loupakis, Fotios, Hurwitz, Herbert I., Saltz, Leonard, Arnold, Dirk, Grothey, Axel, Nguyen, Quynh Lan, Osborne, Stuart, Talbot, Jonathan, Srock, Stefanie, Lenz, Heinz-Josef
Publicado 2018

Modulation of circulating protein biomarkers following TRC105 (anti-endoglin antibody) treatment in patients with advanced cancer

por Liu, Yingmiao, Starr, Mark D, Brady, John C, Dellinger, Andrew, Pang, Herbert, Adams, Bonne, Theuer, Charles P, Lee, Nam Y, Hurwitz, Herbert I, Nixon, Andrew B
Publicado 2014

Safety, pharmacokinetics, and pharmacodynamic properties of oral DEBIO1143 (AT-406) in patients with advanced cancer: results of a first-in-man study

por Hurwitz, Herbert I., Smith, David C., Pitot, Henry C., Brill, Jeffrey M., Chugh, Rashmi, Rouits, Elisabeth, Rubin, Joseph, Strickler, John, Vuagniaux, Gregoire, Sorensen, J. Mel, Zanna, Claudio
Publicado 2015

Plasma-Based Measurements of Tumor Heterogeneity Correlate with Clinical Outcomes in Metastatic Colorectal Cancer

por Yaung, Stephanie J., Ju, Christine, Gattam, Sandeep, Nicholas, Alan, Sommer, Nicolas, Bendell, Johanna C., Hurwitz, Herbert I., Lee, John J., Casey, Fergal, Price, Richard, Palma, John F.
Publicado 2022

A phase I study of ABT-510 plus bevacizumab in advanced solid tumors

por Uronis, Hope E, Cushman, Stephanie M, Bendell, Johanna C, Blobe, Gerard C, Morse, Michael A, Nixon, Andrew B, Dellinger, Andrew, Starr, Mark D, Li, Haiyan, Meadows, Kellen, Gockerman, Jon, Pang, Herbert, Hurwitz, Herbert I
Publicado 2013

The effect of different dosing regimens of motesanib on the gallbladder: a randomized phase 1b study in patients with advanced solid tumors

por Rosen, Lee S, Lipton, Lara, Price, Timothy J, Belman, Neil D, Boccia, Ralph V, Hurwitz, Herbert I, Stephenson Jr, Joe J, Wirth, Lori J, McCoy, Sheryl, Hei, Yong-jiang, Hsu, Cheng-Pang, Tebbutt, Niall C
Publicado 2013

Blood‐based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance)

por Hatch, Ace J., Sibley, Alexander B., Starr, Mark D., Brady, J. Chris, Jiang, Chen, Jia, Jingquan, Bowers, Daniel L., Pang, Herbert, Owzar, Kouros, Niedzwiecki, Donna, Innocenti, Federico, Venook, Alan P., Hurwitz, Herbert I., Nixon, Andrew B.
Publicado 2016

A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours

por Berlin, Jordan, Ramanathan, Ramesh K., Strickler, John H., Subramaniam, Deepa S., Marshall, John, Kang, Yoon-Koo, Hetman, Robert, Dudley, Matthew W., Zeng, Jiewei, Nickner, Caroline, Xiong, Hao, Komarnitsky, Philip, Shepherd, Stacie Peacock, Hurwitz, Herbert, Lenz, Heinz-Josef
Publicado 2018

A phase Ib study of the combination regorafenib with PF-03446962 in patients with refractory metastatic colorectal cancer (REGAL-1 trial)

por Clarke, Jeffrey Melson, Blobe, Gerard C., Strickler, John H., Uronis, Hope Elizabeth, Zafar, S. Yousuf, Morse, Michael, Dropkin, Evan, Howard, Leigh, O’Neill, Margot, Rushing, Christel N., Niedzwiecki, Donna, Watson, Hollie, Bolch, Emily, Arrowood, Christy, Liu, Yingmiao, Nixon, Andrew B., Hurwitz, Herbert I.
Publicado 2019

Randomized Phase II Trial of Parsatuzumab (Anti‐EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First‐Line Metastatic Colorectal Cancer

por García‐Carbonero, Rocío, van Cutsem, Eric, Rivera, Fernando, Jassem, Jacek, Gore, Ira, Tebbutt, Niall, Braiteh, Fadi, Argiles, Guillem, Wainberg, Zev A., Funke, Roel, Anderson, Maria, McCall, Bruce, Stroh, Mark, Wakshull, Eric, Hegde, Priti, Ye, Weilan, Chen, Daniel, Chang, Ilsung, Rhee, Ina, Hurwitz, Herbert
Publicado 2017

Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer: A Randomized Clinical Trial

por Mettu, Niharika B., Ou, Fang-Shu, Zemla, Tyler J., Halfdanarson, Thorvardur R., Lenz, Heinz-Josef, Breakstone, Rimini A., Boland, Patrick M., Crysler, Oxana V., Wu, Christina, Nixon, Andrew B., Bolch, Emily, Niedzwiecki, Donna, Elsing, Alicia, Hurwitz, Herbert I., Fakih, Marwan G., Bekaii-Saab, Tanios
Publicado 2022

Genetic variation determines VEGF-A plasma levels in cancer patients

por Innocenti, Federico, Jiang, Chen, Sibley, Alexander B., Etheridge, Amy S., Hatch, Ace J., Denning, Stefanie, Niedzwiecki, Donna, Shterev, Ivo D., Lin, Jiaxing, Furukawa, Yoichi, Kubo, Michiaki, Kindler, Hedy L., Auman, J. Todd, Venook, Alan P., Hurwitz, Herbert I., McLeod, Howard L., Ratain, Mark J., Gordan, Raluca, Nixon, Andrew B., Owzar, Kouros
Publicado 2018

A phase Ib study of capecitabine and ziv-aflibercept followed by a phase II single-arm expansion cohort in chemotherapy refractory metastatic colorectal cancer

por Strickler, John H., Rushing, Christel N., Niedzwiecki, Donna, McLeod, Abigail, Altomare, Ivy, Uronis, Hope E., Hsu, S. David, Zafar, S. Yousuf, Morse, Michael A., Chang, David Z., Wells, James L., Blackwell, Kimberly L., Marcom, P. Kelly, Arrowood, Christy, Bolch, Emily, Haley, Sherri, Rangwala, Fatima A., Hatch, Ace J., Nixon, Andrew B., Hurwitz, Herbert I.
Publicado 2019

The McCAVE Trial: Vanucizumab plus mFOLFOX‐6 Versus Bevacizumab plus mFOLFOX‐6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC)

por Bendell, Johanna C., Sauri, Tamara, Gracián, Antonio Cubillo, Alvarez, Rafael, López‐López, Carlos, García‐Alfonso, Pilar, Hussein, Maen, Miron, Maria‐Luisa Limon, Cervantes, Andrés, Montagut, Clara, Vivas, Cristina Santos, Bessudo, Alberto, Plezia, Patricia, Moons, Veerle, Andel, Johannes, Bennouna, Jaafar, van der Westhuizen, Andre, Samuel, Leslie, Rossomanno, Simona, Boetsch, Christophe, Lahr, Angelika, Franjkovic, Izolda, Heil, Florian, Lechner, Katharina, Krieter, Oliver, Hurwitz, Herbert
Publicado 2019